Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Journal of Thoracic Oncology ; 17(9):S283, 2022.
Article in English | EMBASE | ID: covidwho-2031519

ABSTRACT

Introduction: Durvalumab received EMA approval as consolidation therapy (CT) for unresectable stage III NSCLC with PD-L1 ≥1% and who did not have progression after CRT. Our objective was to analyze in real clinical practice the effectiveness of durvalumab and explore the clinical factors that may be associated with the benefit from CT. Methods: Retrospective study was made at Hospital of Leon (Spain), including 37 patients with locally advanced NSCLC treated with durvalumab after CRT treatment between March 2018 and october 2021 (40.5% patients were included in the durvalumab early access program). The neutrophil-to-lymphocyte ratio (NLR) could identified after CRT as a factor that may be benefit from durvalumab. Results: Median age was 67 years (range 46-82 years). 40.5% of patients were ≥70 years old. 78.4% were male and 51.4% smokers. 54% had non-squamous histology. PD-L1 expression was <1% in 5% and not available in 8% patients. 2.7% ROS1 rearrangements, 5.4% KRAS mutations and not available in 43.2% patients. Stage IIIA, IIIB, IIIC disease were 24.3%, 54.1% and 21.6%, respectively. Median time from end of CRT to onset durvalumab was 44 days (range 13-120 days). Overall median CT duration was 214.8 days (range 69-399 days) with a median of 14 infusions (range 6-27 infusions). With a median follow up of 19.7 months (range 1.4-34.9 months);67.6% had stopped CT: 37.8% due to completing treatment, 16.2% disease progression, 10.8% adverse event and 2.7% due to COVID19 infection. Median real-world progression-free survival (rwPFS) was 17 months (95% CI, 11-23). Median real-world overall survival (rwOS) was 29.9 months (95% CI, 23.3-36.6). %rwOS at 6, 18 and 24 months were 100%, 86.9% and 74.5%, respectively. For patients with post-CRT NLR not exceeding the cohort median value of 6, receipt of durvalumab was associated with an improvement in rwOS (median not reached vs 25.7 months;p=0.025). 56.8% patients had any grade of radiation pneumonitis (median time from CRT start: 119 days [range 36-241 days]). Of these, 19% patients developed worsening of radiation pneumonitis with durvalumab. 54,1% developed immune-mediated toxicity, mostly G1-2 (85.1%). Conclusions: Our results demonstrate the effectiveness of durvalumab consolidation in this patients population in a real-life setting. We identified low NLR after CRT as a potentially predictive factor for the benefit of CT in locally advanced NSCLC. Keywords: DURVALUMAB, PACIFIC, REAL WORLD DATA

2.
Frontiers in Sustainable Cities ; 4, 2022.
Article in English | Scopus | ID: covidwho-1933926

ABSTRACT

In the original article, there was a wording error on the way that the reduction percentages of air pollutant concentrations were expressed. It is not a reduction percentage but a percentage of increase that would have been observed in the absence of lockdown. A correction has been made to Discussion, “Summary of Findings,” first paragraph: We replaced the following sentences: “The mean reduction in PM10 concentrations was 8.3%, with values ranging from−1.8 to 39.8% depending on the municipality. For NO2 concentrations, the mean reduction was 29.0%, with values ranging from 3.5 to 187.8% depending on the municipality.” by: “The daily mean difference between the estimated PM10 level during lockdown and its reference (modeled concentrations without lockdown) was −8.3 μg.m−3. This difference was −2.1 μg.m−3 for NO2.”.In the original article, there was a mistake in Table 2 as published. The four columns entitled “Reduction percentage” were not defined. The corrected Table 2 appears below. The authors apologize for these errors and state that this doesnot change the scientific conclusions of the article in any way. The original article has been updated. Copyright © 2022 Adélaïde, Medina, Wagner, de Crouy-Chanel, Real, Colette, Couvidat, Bessagnet, Alter, Durou, Host, Hulin, Corso and Pascal.

3.
Cuadernos de Psicologia del Deporte ; 22(2):33-46, 2022.
Article in Spanish | CAB Abstracts | ID: covidwho-1898005

ABSTRACT

A new virus called COVID-19, began to spread in Wuhan (China) since the end of 2019, and is now found all over the world. This virus, in addition to increasing the risk of death from infection, also increases psychological pressure on humanity. Samples were taken from college students from the different UANL faculties, using cluster sampling, which responded to a battery of questionnaires that included the 7-item Generalized Anxiety Disorder Scale (GAD-7) and those asking about the basic information of participants. We received 1,658 responses. 1,658 responses were received. The results indicated that 0.6% of the respondents experienced severe anxiety, 1.8% moderate anxiety, and 12.1% mild anxiety. Likewise, the factors Living in Urban Areas (OR = 0.818, 95% CI = 0.702 - 0.914), Stability of Family Income (OR = 0.723, 95% CI = 0.633 - 0.807) and Living with Parents (OR = 0.752, 95 CI % = 0.585 - 0.952) were protective against anxiety. Practicing a team sport was a risk factor for anxiety. According to the study, it is suggested that sports students' mental health be monitored during the contingency caused by the COVID19 epidemic.

4.
Cuadernos de Psicología del Deporte ; 22(2):33-46, 2022.
Article in Spanish | ProQuest Central | ID: covidwho-1888018

ABSTRACT

Un nuevo virus denominado COVID-19, comenzó a esparcirse en Wuhan (China) desde finales del 2019, y ahora se encuentra por todo el mundo. Este virus, además de aumentar el riesgo de muerte por infección, también aumenta la presión psicológica en la humanidad. Se tomaron muestras de estudiantes universitarios de las diferentes facultades de la UANL, mediante el uso de muestreo conglomerados, los cuales respondieron a una batería de cuestionarios que incluía la Escala de Trastorno de Ansiedad Generalizada conformada de 7 ítems (GAD-7). Se recibieron 1,658 respuestas. Los resultados indicaron que el 0,6% de los encuestados experimentaron ansiedad severa, el 1.8% ansiedad moderada y 12,1% ansiedad ligera. Asimismo, los factores Viviendo en Áreas Urbanas (RM = 0.818, IC 95% = 0.702 - 0.914), Estabilidad de Ingresos Familiares (RM = 0.723, IC 95% = 0.633 - 0.807) y Viviendo con Padres (RM = 0.752, IC 95% = 0.585 - 0.952) fueron protectores contra la ansiedad. Practicar un deporte colectivo fue un factor de riesgo para la ansiedad. Según el estudio se sugiere que la salud mental de los deportistas sea controlada durante la contingencia provocada por la epidemia del COVID-19.Alternate :A new virus called COVID-19, began to spread in Wuhan (China) since the end of 2019, and is now found all over the world. This virus, in addition to increasing the risk of death from infection, also increases psychological pressure on humanity. Samples were taken from college students from the different UANL faculties, using cluster sampling, which responded to a battery of questionnaires that included the 7-item Generalized Anxiety Disorder Scale (GAD-7) and those asking about the basic information of participants. We received 1,658 responses. 1,658 responses were received. The results indicated that 0.6% of the respondents experienced severe anxiety, 1.8% moderate anxiety, and 12.1% mild anxiety. Likewise, the factors Living in Urban Areas (OR = 0.818, 95% Cl = 0.702 - 0.914), Stability of Family Income (OR = 0.723, 95% Cl = 0.633 - 0.807) and Living with Parents (OR = 0.752, 95 Cl % = 0.585 - 0.952) were protective against anxiety. Practicing a team sport was a risk factor for anxiety. According to the study, it is suggested that sports students' mental health be monitored during the contingency caused by the COVID19 epidemicAlternate :Um novo vírus denominado COVID-19, começou a se espalhar em Wuhan (China) desde o final de 2019, e agora é encontrado em todo o mundo. Esse vírus, além de aumentar o risco de morte por infecção, também aumenta a pressão psicológica sobre a humanidade. Amostras de atletas das diferentes faculdades da UANL foram obtidas por meio de amostragem por conglomerado, que respondeu a uma bateria de questionários que incluiu a Escala de Transtorno de Ansiedade Generalizada composta por 7 itens (GAD-7). 1,658 respostas foram recebidas. Os resultados indicaram que 0,6% dos entrevistados experimentaram ansiedade severa, 1.8% ansiedade moderada e 12.1% ansiedade leve. Da mesma forma, os fatores Morar em Áreas Urbanas (OR = 0.818, IC 95% = 0.702 - 0.914), Estabilidade da Renda Familiar (OR = 0.723, IC 95% = 0.633 - 0.807) e Morar com os Pais (OR = 0.752, IC 95 % = 0.585 - 0.952) eram protetores contra a ansiedade. Praticar um esporte coletivo era um fator de risco para ansiedade. De acordo com o estudo, sugere-se que a saúde mental dos alunos seja acompanhada durante o contingente causado pela epidemia de COVID-19.

5.
Cuadernos de Psicologia del Deporte ; 22(2):33-46, 2022.
Article in English, Portuguese, Spanish | Scopus | ID: covidwho-1863217

ABSTRACT

A new virus called COVID-19, began to spread in Wuhan (China) since the end of 2019, and is now found all over the world. This virus, in addition to increasing the risk of death from infection, also increases psychological pressure on humanity. Samples were taken from college students from the different UANL faculties, using cluster sampling, which responded to a battery of questionnaires that included the 7-ítem Generalized Anxiety Disorder Scale (GAD-7) and those asking about the basic information of participants. We received 1,658 responses. 1,658 responses were received. The results indicated that 0.6% of the respondents experienced severe anxiety, 1.8% moderate anxiety, and 12.1% mild anxiety. Likewise, the factors Living in Urban Areas (OR = 0.818, 95% CI = 0.702 - 0.914), Stability of Family Income (OR = 0.723, 95% CI = 0.633 - 0.807) and Living with Parents (OR = 0.752, 95 CI % = 0.585 - 0.952) were protective against anxiety. Practicing a team sport was a risk factor for anxiety. According to the study, it is suggested that sports students' mental health be monitored during the contingency caused by the COVID-19 epidemic © 2022. All Rights Reserved.

6.
Hematology, Transfusion and Cell Therapy ; 43:S531, 2021.
Article in Portuguese | EMBASE | ID: covidwho-1859742

ABSTRACT

Objetivos: Avaliar a incidência e evolução clínica da COVID-19 em pacientes com leucemia mieloide crônica (LMC) acompanhados em dois centros. Materiais e métodos: Estudo prospectivo, observacional, em andamento. Os pacientes responderam a dois questionários com 6 meses de intervalo. Foram incluídas perguntas relacionadas a sintomas, comorbidades, incidência e suspeita de COVID-19, contatos com pessoas infectadas, comportamento durante a pandemia, gravidade da infecção e vacinação. Cada questionário avaliou dados referentes aos últimos 6 meses. Adicionalmente, foram obtidos dados clínicos, laboratoriais e de tratamento dos prontuários médicos.Os dados foram coletados e armazenados no sistema REDCap. Resultados: Entre setembro de 2020 e julho de 2021, 225 pacientes responderam ao primeiro questionário e 121 também responderam ao segundo. Dos analisados, 127 (56,4%) eram homens. A mediana de idade 56,5 anos (19-90). A maioria estava em tratamento com inibidores de tirosina quinase (88.5%) e 11.5% sem tratamento, em protocolo de descontinuação. 80% dos pacientes realizaram distanciamento social e 30% dos avaliados tiveram algum familiar ou contato próximo com COVID-19. Nos 6 meses anteriores à aplicação do primeiro questionário, 49 (21,9%) tiveram sintomas respiratórios, 30 (13,4%) febre, 7 (3,1%) pneumonia e 45 (20,1%) falta de ar ou tosse seca. Comorbidades: 79 (35,6%) hipertensão, 34 (15,3%) diabetes, 15 (6,8%) insuficiência renal, 13 (5,9%) doença pulmonar, 37 (16,7%) cardiopatia e 43 (19,4%) outra doença crônica. No total, 28 (12,4%) pacientes foram diagnosticados com COVID-19, enquanto 10 foram suspeitos. A mediana de idade foi 47 anos, 67,9% eram homens;10 (37,0%) não estavam respeitando o distanciamento social. 36% tinham comorbidades: 12% diabetes, 28% hipertensão, 4% insuficiência renal, 24% cardiopatia e 12% outra doença crônica. 12 tiveram algum familiar ou contato próximo diagnosticado com COVID-19. Vinte e seis (92%) pacientes tiveram forma leve, sem necessidade de internação, um paciente de 71 anos em uso de nilotinibe e em RMM teve quadro grave, com óbito. 27 pacientes estavam na fase crônica e um em fase acelerada. Treze apresentavam resposta molecular maior, um resposta hematológica, 4 resposta citogenética completa, 3 MR4.0 e 7 MR4.5. Tratamento vigente: imatinibe (16), dasatinibe(5), nilotinibe (5) e um sem tratamento. Houve um caso de reinfecção. Até o momento, 84 (37%) dos pacientes receberam vacinas para a COVID-19 (32 CoronaVac, 51 Oxford/AstraZeneca e um da Pfizer). Dentre os pacientes vacinados, 22 apresentaram reações adversas: 8 apresentaram febre, 6 dor de cabeça e 20 outros (dores no corpo, calafrios ou dores no local da injeção). Discussão: Pacientes com neoplasias hematológicas tem quadro mais grave e maior mortalidade associada a COVID-19. Na LMC a mortalidade parece ser levemente superior à da população geral, com pior evolução nas fases mais avançadas e em pacientes com comorbidades. Tivemos um caso de óbito e um de reinfecção, onde não podemos descartar a hipótese de uma variante. Conclusão: A incidência de COVID-19 na população de LMC estudada foi de 12,4%, mais frequente em homens, com menor mediana de idade e menor taxa de isolamento social, com predomínio de casos leves e moderados. Todos os casos descritos ocorreram antes da vacinação.

7.
Hematology, Transfusion and Cell Therapy ; 43:S511-S512, 2021.
Article in Portuguese | EMBASE | ID: covidwho-1859707

ABSTRACT

Objetivos: Analisar a incidência e evolução clínica da COVID-19, em pacientes com neoplasias mieloproliferativas Filadélfia negativas (NMP) acompanhadas em um único centro. Materiais e métodos: Estudo prospectivo, unicêntrico, observacional, em andamento. Foram aplicados dois questionários aos pacientes com NMP em seguimento ambulatorial, com um intervalo de 6 meses e coletados dados clínicos e laboratoriais dos prontuários médicos. Através dos questionários, buscamos identificar casos confirmados e suspeitos de COVID-19, avaliar dados comportamentais durante a pandemia, exposição, vacinação e analisar os fatores de risco para gravidade e prognóstico. Os dados foram coletados e armazenados no sistema REDCap. Resultados: Entre novembro/2020 e julho/2021, foram avaliados 145 pacientes, 65 (44,8%) com trombocitemia essencial (TE), 40 (27,6%) com policitemia vera (PV), 33 (22,8%) com mielofibrose primária (MF) e 7 (4,8%) com NMP não-classificadas. A mediana de idade foi de 67,4 anos;65,5% eram mulheres;86,1% apresentaram alguma comorbidade, sendo as mais prevalentes hipertensão (51,8%), diabetes (17,5%) e cardiopatias (13,1%). A adesão ao isolamento social foi de 82,8%. 9% dos pacientes receberam a primeira dose da vacina para COVID-19 e 11% receberam as duas doses, sendo 57,1% CoronaVac, 39,3% Oxford/Astrazeneca e 3,6% Pfizer. Nove pacientes (6,2%) tiveram diagnóstico confirmado de COVID-19 (por PCR ou sorologia) e 5 (3,4%) quadro clínico suspeito. Dentre os casos confirmados, sete eram TE e 2 PV, com mediana de idade de 44 anos. Quatro estavam em uso de hidroxiureia (HU) e AAS, um HU e um sem tratamento. Sete casos foram leves e dois moderados, com hospitalização, mas sem necessidade de ventilação mecânica ou oxigênio. Não houve óbitos por COVID-19. Seis pacientes afirmaram seguir as medidas de isolamento social e três haviam recebido a primeira dose da vacina, sendo que em dois casos a infecção ocorreu após o início da vacinação (um após a vacina Oxford/Astrazeneca e o outro após as duas doses da CoronaVac). Discussão: A alta faixa etária dos pacientes com NMP e a alta prevalência de comorbidades são fatores de risco e vulnerabilidade à COVID-19. As NMP possuem maior risco de complicações tromboembólicas e hemorrágicas e nível aumentado de citocinas pró-inflamatórias, principalmente na MF, que tornariam esta população mais suscetível a formas mais graves da COVID-19. Um estudo italiano mostrou uma alta taxa de mortalidade pela COVID em pacientes com NMP (33%). Observamos uma incidência de COVID-19 menor do que a observada na população geral (8,7%), que pode ser relacionada à alta adesão ao isolamento social nos pacientes mais idosos. A mediana de idade dos casos de COVID foi menor do que a do grupo total, possivelmente pela maior exposição desses pacientes. Pelo tamanho da amostra não foi possível analisar letalidade e gravidade. Conclusão: Observamos uma frequência maior de COVID-19 em pacientes mais jovens, com TE e PV. As medidas preventivas devem ser mantidas, pois foram observados casos pós vacinação. Pelas características do estudo, não foram detectados casos graves, mas serão rastreados os pacientes com perda de seguimento durante a pandemia e que não responderam aos questionários, no intuito de identificar mortes por COVID-19 nessa população.

8.
Hematology, Transfusion and Cell Therapy ; 43:S131-S132, 2021.
Article in Portuguese | EMBASE | ID: covidwho-1859604

ABSTRACT

Objetivos: Avaliar a efetividade e eficiência de um protocolo de descontinuação de inibidores de tirosina quinase (ITK) em tratamento no Sistema Único de Saúde (SUS) que incluiu uma fase de descalonamento de dose antes da interrupção do tratamento. Materiais e métodos: Estudo prospectivo, em andamento. Critérios de inclusão: LMC em fase crônica, em tratamento com ITK no mínimo há 3 anos, transcritos BCR-ABL típicos, com resposta molecular profunda (RMP) por 2 anos (MR4.5) Exclusão: fase avançada prévia ou atual, resistência prévia, mutações do ABL. Antes da suspensão do tratamento, foi realizado o descalonamento do ITK para 50% da dose atual por 6 meses. Durante a fase de descalonamento foi realizado monitoramento de PCR quantitativo para BCR-ABL (PCRq) mensal. Após a descontinuação do ITK o paciente foi seguido com avaliações clínicas, hemograma e PCRq a cada 4 semanas no primeiro semestre, a cada 2 meses no segundo semestre e no segundo ano e depois a cada 3 meses. A terapia foi reiniciada na perda de RMM (PCRq<0.1%). Resultados: Entre setembro de 2020 e julho de 2021 foram triados 213 pacientes com LMC;28 eram potencialmente elegíveis: 9 não aceitaram participar;19 assinaram o TCLE e um paciente teve falha de screening. A mediana de idade dos 18 participantes foi de 61.5 anos (35-86), 61% homens, 44.4% Sokal baixo risco ao diagnóstico, 15.1% intermediário/alto;81% com transcrito BCR-ABL do tipo b3a2;78% estavam em uso de Imatinibe,11% Dasatinibe,5.5% Nilotinibe e 5.5% Bosutinibe. A mediana da duração do tratamento com ITK até o início do descalonamento foi de 136 meses (46-201);a duração da RM 4.5 foi de 104, 5 meses (27-168);a mediana do tempo entre suspensão e perda de RMM foi de 2.5 meses (2-3). Oito pacientes perderam a RM4.5 durante a fase de descalonamento: destes, 2 perderam RMM, um na fase de descalonamento e outro na fase de descontinuação. Status atual: sete pacientes estão na fase de descontinuação, 8 na fase de descalonamento e 3 pacientes (16.6%) apresentaram recaída molecular. Não houve nenhum evento adverso sério. Dois pacientes tiveram Covid-19 (leve) na fase de descalonamento. Discussão: a descontinuação tem sido proposta como estratégia terapêutica na prática clínica nos pacientes com LMC com RM profunda sustentada. Nesses casos, a chance de sobrevida livre de remissão é de 50%. Poucos estudos avaliaram o efeito da retirada gradual do ITK antes da interrupção. No estudo DESTINY, o descalonamento foi feito por 12 meses, e a sobrevida livre de terapia aos 36 meses foi de 72% nos pacientes com RM4.0. Nos resultados preliminares do nosso estudo, ainda em recrutamento de pacientes, com 10 meses de seguimento, observamos que das 3 recaídas, uma delas ocorreu na fase de descalonamento, em um paciente em uso de nilotinibe em segunda linha e outra em um paciente na segunda tentativa de descontinuação, onde é esperado uma menor chance de sucesso. Conclusões: até o momento o protocolo mostrou-se seguro, com resultados dentro do esperado na literatura. O seguimento a longo prazo e inclusão de novos pacientes nos permitirá avaliar se a estratégia do descalonamento trará vantagem na sobrevida livre de terapia.

10.
Blood ; 138:4601, 2021.
Article in English | EMBASE | ID: covidwho-1582263

ABSTRACT

Introduction: COVID-19 has severely affected the Brazilian population. By July 2021, the incidence was 19,9 million cases and 556.000 deaths. Recent studies suggest that patients with MPN have higher infection and death rates than the general population. Older age and comorbidities are risk factors for severe COVID-19 in CML and MPN. Objectives This study aimed to evaluate the incidence and clinical evolution of COVID-19 in a cohort of CML and MPN Brazilian patients. Methods This is a prospective, observational, ongoing study. All patients signed informed consent and answered two structured questionnaires within a six months interval. The questionnaire included questions about patient's behavior during pandemic, symptoms, contacts, COVID-19 infection, and vaccination data in the last six months. In addition, demographic data, CML and NMP treatment, comorbidities, laboratory tests, COVID severity, and outcome were collected from the medical records. Results From September 2020 to July 2021, 370 patients answered the first questionnaire, and 153 answered the second: 225 with CML and 145 with MPN (45% essential thrombocythemia, 27.6%, polycythemia vera, 23% myelofibrosis, and 4.8% not classified). In the CML population, the median age was 56 (19-90). Most were receiving tyrosine kinase inhibitors (88,5%) and 26 (11,5%) no treatment, in treatment-free remission (TFR). 80% of the patients were practicing social distancing, and 30% had at least one family member or close contact diagnosed with COVID-19. Comorbidities: hypertension (35%), diabetes (14%), pulmonary disease (6%), cardiac disease (16%), renal disease (7%), other (18%). A total of 28/225 (12.4%) patients had confirmed COVID-19 diagnosis (by serology or PCR), while 10 were suspect. The median age was 47 years, 68% were male, and 41% were not respecting social distancing. Thirty-five percent had comorbidities: 25% hypertension;68% had a history of close contact with an infected person. One patient was in the accelerated phase, and 27 were in the chronic phase;4 had a complete cytogenetic response, 13 major molecular response (MMR), 3 MR4.0, and 7 MR4.5. COVID-19 was mild/moderate in 27 and in severe in one case, resulting in death. This patient was a male, 71-year-old, with hypertension, in MMR with nilotinib. At COVID-19 onset, 16 pts were receiving imatinib, five dasatinib;five nilotinib e 2 were in TFR. There was one reinfection, in a 54 years old male patient, with no comorbidities. To date, 84 (37%) patients (pts) have received vaccines against COVID-19: 32 CORONAVAC (Sinovac/Butantan), 51 ChAdOx1nCov-19-Covishield (Astrazeneca/Oxford), and one BNT162 (Pfizer). All COVID-19 cases occurred before vaccination. Among the 145 MPN pts, the median age was 67 years (29-90), and 86% had comorbidities (52% hypertension, 17.5% diabetes, and 13% cardiac diseases). Social distancing was 83%. Nine out of 145 (6.2%) had confirmed COVID-19 diagnosis, and 3% suspect. The median age of these pts was 43 years (28-80). Seven patients had ET and 2 PV. Seven were female. Four pts received Hydroxyurea (HU) and aspirin, four aspirin, one HU, and one no treatment. There were seven mild and two moderate cases requiring hospitalization, none requiring oxygen or mechanical ventilation, none with thrombosis. Two COVID cases occurred after the first dose of vaccines (CORONAVAC and Covishield). In the whole MPN group, 11% have received two doses (57% CORONAVAC, 40% Covishield, and 3.6% BNT 162). Conclusions COVID-19 cases occurred more frequently in younger patients. COVID-19 incidence was higher in the CML than in the MPN population, probably because MPN patients were less exposed, and the older pts were the first to receive vaccines. The impact of the vaccination on the prevention of new cases will be evaluated during the follow-up. Disclosures: Bortolini: Novartis: Speakers Bureau. Pagnano: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau;Astellas: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau;intpharma: Other: Lecture;EMS: Other: Lecture;Jansenn: Other: Lecture.

11.
Bulletin Epidemiologique Hebdomadaire ; 13:232-242, 2021.
Article in French | GIM | ID: covidwho-1489278

ABSTRACT

Background - The reduction of socioeconomic activities related to the spring 2020 lockdown implemented to limit the spread of COVID-19 in France led to decreases in air pollutant concentrations. Methods - The quantitative health impact assessment method was used to estimate the impact on mortality of the French population: 1/in the short- and longer term, impacts of the decreases in particulate matter (PM10 and PM2,5) and nitrogen dioxide (NO2) levels observed during the lockdown;and 2/in the long term, impact on the total burden for the years 2016-2019. Results - The limiting of socioeconomic activities in the spring of 2020 reduced NO2 and PM population's exposures that resulted in 2,300 deaths avoided in relation to PM and nearly 1,200 in relation to NO2. The long-term impact of air pollution on mortality is estimated at nearly 40,000 annual deaths attributable to PM2.5 exposure and nearly 7,000 deaths attributable to NO2 exposure. Conclusion - These results show that short-term reductions in air pollution levels are associated with rapid, measurable health benefits. They confirm that even short-term public actions that reduce air pollution levels (different from lockdown, which is obviously not desirable) appear to have a significant impact on health. Moreover, the results underline that on the long-term, although mortality related to ambient air pollution shows a slight downward trend, it remains a significant risk factor in France. Therefore, efforts to reduce air pollution and associated mortality must be pursued lastingly for all sources of air pollution through tailored, ambitious policies.

12.
HemaSphere ; 5(SUPPL 2):584, 2021.
Article in English | EMBASE | ID: covidwho-1393476

ABSTRACT

Background: Although initially considered at higher risk for severe presentations of COVID-19, observational studies with SCD patients have mostly pointed to clinical severity similar to the general population. However, the level of vulnerability of these individuals to become infected and the determinants for their contagion are still uncertain. Aims: To assess the prevalence of SARS-Cov-2 antibodies in SCD patients followed at a Brazilian center and its correlation with phenotypic and socioeconomic determinants. Methods: A questionnaire was applied regarding demographics, socioeconomic status, use of Hydroxyurea, working status and income, COVID-19 symptoms, and the perceptions about social isolation measures. Blood samples were taken for chemoluminescence IgG (anti-N) and IgM (anti-S) anti-SARS-CoV-2 tests (Abbott Architect™, Ireland);specific neutralizing antibody titers were accessed observing the cytopathic effect in cells incubated with patient serum-virus mixture. Results: From Jul/20 to Jan/21, 214 serological tests were performed on135 patients (86% of SCD patients registered at the center): 82 HbSS (61%), 41HbSC (30%), 8Sβ+ (6%), 4Sβ0 (3%);57% male and median age 42 (19-74). 66% were using Hydroxyurea and 4% were on chronic transfusion. In the analyzed period, 61 (45%) patients had vasoocclusive crises;37 (27%) had symptoms suggestive of COVID-19, but only 2 patients had a positive PCR for SARS-Cov-2. When questioned, only12% of patients did not consider themselves vulnerable to infection, and only17% believed that individual and collective protection measures were expendable. In fact, 91% stated that they were able to adopt basic social distance measures, with 76% reporting cancellation of social events and 64% managed to reduce the use of public transport, but only 44% could work or study remotely. Regarding serological evaluation, 57 patients (42%) were tested more than1 time during this period: 46 with 2 tests,11 with ≥ 3 tests. Among all patients,15 had positive results: 9 IgG/IgM+ and 6 IgG+ only, therefore with an overall seroprevalence of11%. Seroconversion was documented for only1 patient during the study period and, interestingly, with no signs and symptoms of infection. Moreover, 2 patients lost positivity for IgG 3 months after the initial positive test. The search for functionally neutralizing antibodies resulted in 9 patients with low titers (□1:40) and only 3 patients with remarkably high titers (≥1:640). There were no correlations between test positivity and education, income, number of household contacts and maintenance of work outside the home;however, serological positivity was associated with older age (40.3 x 22.9, p<.001) and regular use of public transport (Fisher exact test, p=0.02). Only1 patient in this cohort needed hospitalization for COVID-19, including mechanical ventilation and exchange transfusions, but was discharged after14 days Summary/Conclusion: These data attest to the effectiveness of social distancing instructions given to patients in our SCD clinic throughout the pandemic, considering the low overall positivity and only1 seroconversion during the study period. The fact that only1 patient in our center had severe disease agrees with other reports showing less severity for SCD than initially expected. In fact, the transient positivity of serological tests and the low levels of functional neutralizing antibodies in SCD patients may indicate the acquisition of protective immune responses that are not dependent on antibodies and that still need to be better evaluated.

13.
Linguistica Y Literatura ; - (80):203-220, 2021.
Article in English | Web of Science | ID: covidwho-1350576

ABSTRACT

This article presents the preliminary results of an Emergency Remote Teaching (ERT) experience (Hodges, Moore, Lockee, Trust & Bond, 2020) of a foreign language professor during the COVID-19 pandemic. Using a qualitative methodology, technological and educational obstacles were found, such as participation in videoconferences, the implementation of real tasks, the use of humor and the motivation of students. It is concluded that the lecturer gained confidence and expertise in an interactive environment. Finally, the promotion of interaction and alternative and formative evaluation in class is recommended.

14.
Revista de Investigacion Cientifica REBIOL ; 40(2):170-176, 2020.
Article in Spanish | CAB Abstracts | ID: covidwho-1328321

ABSTRACT

The megadiversity of Peru, has many species framed in the genus Cinchona, Ladenbergia and Remijia, and that the inhabitants of the Andean-Amazonian Communities know them indistinctly as "quina trees", "quina" or "cascarillas" and which They attribute medicinal properties to them against malaria, broncho-respiratory diseases and especially Covid-19. However, the indiscriminate exploitation and the little interest of the investigation has contributed to the extinction and confusion in the identification of the species in different genera;In view of this, the research objective was to quantify the alkaloids of Ladenbergia oblongifolia "quina tree";in order to promote the revaluation of this species as a promising ethnobotanical resource that seeks to correlate its active principles or secondary metabolites with the consequent pharmacological actions attributed to it. For this, bark and leaves of L. oblongifolia were used, from Chiclin, Chicama, Ascope, La Libertad, Peru;the taxonomic determination was carried out in the Herbarium Truxillense (HUT);while the extraction and quantification of alkaloids in the Laboratory of Instrumental Methods, Department of Chemistry, Faculty of Chemical Engineering of the National University of Trujillo. It is concluded that the leaves of L. oblongifolia contain 0.1039 mmol alkaloids/g dry matter, and these metabolites can be extracted directly from the leaves, without the need to cut or destroy the trees, so it is urgent to implement mechanisms of use of the leaves instead of the bark, thus avoiding their extinction.

SELECTION OF CITATIONS
SEARCH DETAIL